MBX Biosciences, Inc. (MBX) AI Stock Analysis

• Market Cap: $406.11M
• Dividend Yield: N/A
• Average Volume (3M): 327.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.31
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -1.85
• Shares Outstanding: 33,424,370
• 10 Day Avg. Volume: 220,468
• 30 Day Avg. Volume: 327,231
• PEG Ratio: 0.46
• Price to Book (P/B): 1.44
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $39.00
• Price Target Upside: 220.99% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

MBX Biosciences faces significant challenges with its zero revenue and increasing losses, heavily impacting financial performance. Bearish technical indicators and valuation concerns compound the risks. While the strategic board appointment is a positive step, it does not offset the primary financial and operational difficulties.

Positive Factors

Competitive Advantage

MBX is a potentially better and differentiated option, with weekly dosing vs Yorvipath daily.

Market Potential

The U.S. total addressable market for hypoparathyroidism is over $15 billion, with MBX's lead candidate canvuparatide expected to capture significant sales due to its patient-friendly weekly dosing.

Negative Factors

Safety Concerns

Instances of Grade 3 injection site reactions were observed, though 88% were mild or moderate and resolved within about 7 days.

Stock Volatility

Stock traded down due to investor profit-taking and confusion around PD serum calcium levels in healthy volunteers.

MBX Biosciences, Inc. Business Overview & Revenue Model

Company Description

MBX Biosciences, Inc. (MBX) is a biotechnology company focused on the discovery and development of peptide therapeutics to address unmet needs in endocrine disorders. The company leverages its proprietary platform to create novel therapies aimed at improving the lives of patients with complex hormonal conditions. MBX's core products are in various stages of clinical development, targeting specific endocrine diseases where current treatment options are limited or inadequate.

How the Company Makes Money

MBX Biosciences makes money primarily through the development and commercialization of its peptide-based therapeutics. The company generates revenue by out-licensing its drug candidates to larger pharmaceutical companies capable of taking them through late-stage clinical trials, regulatory approval, and market launch. Additionally, MBX may enter into strategic partnerships and collaborations to co-develop or co-commercialize its products, which can include upfront payments, milestone payments, and royalties on product sales. The company may also receive funding through grants and research collaborations with academic institutions and other biotech firms.

MBX Biosciences, Inc. Financial Statement Overview

Summary

MBX Biosciences, Inc. struggles with financial health due to zero revenue and significant operational losses. Despite improvements in equity and cash position, the lack of income and high cash burn pose major risks. Reliance on external financing is not sustainable without a viable revenue model.

Income Statement

MBX Biosciences, Inc. has reported zero revenue across all periods, indicating no income generation from its operations. The company has high negative EBIT and net income, reflecting significant operational losses. Financial performance is concerning with no revenue growth and deteriorating margins, all of which are negative.

Balance Sheet

The balance sheet shows a strong cash position with a significant increase in cash and short-term investments in the latest period. Although the company has low debt levels, its negative equity in prior years has now turned positive, indicating an improvement in financial stability. However, the absence of revenue poses a risk to sustainability.

Cash Flow

Cash flows are negative, with increasing operating losses and negative free cash flow, indicating substantial cash burn. The company relies heavily on financing activities to maintain its cash position, raising concerns about long-term cash flow sustainability without revenue generation.

Breakdown
Dec 2024	Dec 2023	Dec 2022
Income Statement		Total Revenue
0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00
	EBIT
-68.19M	-35.31M	-25.16M
	EBITDA
-67.95M	-35.15M	-25.70M
	Net Income Common Stockholders
-61.92M	-32.56M	-26.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
262.15M	80.68M	42.46M
	Total Assets
268.54M	84.18M	45.09M
	Total Debt
171.00K	324.00K	461.00K
	Net Debt
-49.18M	-30.20M	-23.75M
	Total Liabilities
11.09M	156.65M	87.70M
	Stockholders Equity
257.44M	-72.47M	-42.60M
Cash Flow		Free Cash Flow
-55.55M	-32.11M	-23.56M
	Operating Cash Flow
-54.68M	-31.98M	-23.12M
	Investing Cash Flow
-160.59M	-30.93M	-11.41M
	Financing Cash Flow
234.10M	69.22M	46.06M

MBX Biosciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.20%	2.82%	16.59%	-0.39%
ABEO	50 Neutral	$318.71M	―	-271.78%	―	-100.00%	30.33%
OLMA	46 Neutral	$328.42M	―	-41.59%	―	―	0.42%
SLDB	44 Neutral	$224.79M	―	-55.30%	―	―	37.17%
ITOS	42 Neutral	$321.88M	―	-23.68%	―	―	14.60%
ENGN	42 Neutral	$199.69M	―	-44.21%	―	―	―
MBX	38 Underperform	$406.11M	―	-48.22%	―	―	―

MBX Biosciences, Inc. Corporate Events

MBX Biosciences Appoints Steve Hoerter to Board

On April 7, 2025, MBX Biosciences announced the appointment of Steve Hoerter as an independent director to its Board of Directors. Hoerter, a veteran pharmaceutical executive with over three decades of experience, is expected to contribute significantly to the company’s growth and development of its pipeline in endocrine and metabolic disorders. This strategic move is anticipated to enhance MBX’s competitive positioning and operational capabilities as it seeks to deliver innovative treatments to underserved patients.

Spark’s Take on MBX Stock

According to Spark, TipRanks’ AI Analyst, MBX is a Neutral.

MBX Biosciences faces significant challenges, primarily due to its lack of revenue generation and increasing net losses. While financially stable in terms of equity, the company’s heavy reliance on financing is a risk if funding opportunities diminish. Bearish technical indicators and a lack of clear valuation metrics compound the uncertainty. The recent negative market response to earnings highlights potential investor concerns about future prospects.

To see Spark’s full report on MBX stock, click here.